Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Non-aspirin NSAID use and ovarian cancer mortality

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

  3. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. HPV-prevalence in elderly women in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Shared heritability and functional enrichment across six solid cancers

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of CIN2+ following a diagnosis of genital warts: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Preclinical studies suggest that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) may improve survival of ovarian cancer. We examined the association between non-aspirin NSAID use and ovarian cancer mortality.

METHODS: All women in Denmark with a first diagnosis of epithelial ovarian cancer between 2000 and 2012 were identified. We obtained information on drug use, mortality outcomes, and potential confounding factors from nationwide registries. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between postdiagnosis non-aspirin NSAID use (≥1 prescription) and ovarian cancer-specific or other-cause mortality compared with non-use (no prescriptions). The influence of competing risks was evaluated using the sub-distribution hazards model proposed by Fine and Gray.

RESULTS: Among 4117 patients, any postdiagnosis use of non-aspirin NSAIDs was not associated with either ovarian cancer (HR = 0.97, 95% CI = 0.87-1.08) or other-cause (HR = 0.99, 95% CI = 0.77-1.27) mortality, however, inverse associations for ovarian cancer mortality were observed with high cumulative (HR = 0.75, 95% CI = 0.60-0.94) or high-intensity (HR = 0.86, 95% CI = 0.72-1.03) postdiagnosis use of non-aspirin NSAIDs. The associations differed substantially with histological subtype of ovarian cancer, with only inverse associations observed for serous ovarian cancer (HR = 0.87, 95% CI = 0.77-0.99). Among a smaller number of patients with a non-serous tumor, postdiagnosis non-aspirin NSAID use was associated with increased ovarian cancer mortality.

CONCLUSIONS: Any postdiagnosis use of non-aspirin NSAIDs did not influence ovarian cancer mortality overall, however, more intensive use was associated with improved survival of serous ovarian cancer.

Original languageEnglish
JournalGynecologic Oncology
Volume150
Issue number2
Pages (from-to)331-337
Number of pages7
ISSN0090-8258
DOIs
Publication statusPublished - Aug 2018

    Research areas

  • Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Carcinoma, Ovarian Epithelial, Cohort Studies, Cystadenocarcinoma, Serous/diagnosis, Denmark/epidemiology, Female, Humans, Middle Aged, Neoplasms, Glandular and Epithelial/diagnosis, Ovarian Neoplasms/diagnosis, Proportional Hazards Models, Time Factors

ID: 56089900